CAMPAS C ET AL: "AVE-0010 GLP-1 Receptor Agonist Treatment of Diabetes", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 33, no. 10, 1 October 2008 (2008-10-01), pages 838-840, XP002572655, ISSN: 0377-8282, DOI: 10.1358/DOF.2008.33.10.1265206 (B1)

CHRISTENSEN M ET AL: "Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus", I DRUGS: THE INVESTIGATIONAL DRUGS JOURNAL, CURRENT DRUGS LTD, GB, vol. 12, no. 8, 1 August 2009 (2009-08-01) , pages 503-513, XP009163477, ISSN: 2040-3410 (B1)

HAMILTON ALISON ET AL: "Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system.", NEUROREPORT 26 AUG 2009 LNKD- PUBMED:19617854, vol. 20, no. 13, 26 August 2009 (2009-08-26), pages 1161-1166, XP009163504, ISSN: 1473-558X (B1)

HOLSCHER CHRISTIAN: "Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.", RECENT PATENTS ON CNS DRUG DISCOVERY JUN 2010 LNKD- PUBMED:20337586, vol. 5, no. 2, June 2010 (2010-06), pages 109-117, XP009163506, ISSN: 2212-3954 (B1)

HUNTER KERRY ET AL: "Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis", BMC NEUROSCIENCE, BIOMED CENTRAL, LONDON, GB, vol. 13, 1 January 2012 (2012-01-01), page 6pp, XP009163466, ISSN: 1471-2202 (B1)

KASTIN A J ET AL: "Entry of exendin-4 into brain is rapid but may be limited at high doses.", INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS : JOURNAL OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF OBESITY MAR 2003 LNKD- PUBMED:12629557, vol. 27, no. 3, March 2003 (2003-03), pages 313-318, XP009163491, ISSN: 0307-0565 (B1)

WO-A2-2012/177929 (B1)

MCCLEAN PAULA L ET AL: "The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.", THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE 27 APR 2011 LNKD- PUBMED:21525299, vol. 31, no. 17, 27 April 2011 (2011-04-27), pages 6587-6594, XP009163492, ISSN: 1529-2401 (B1)

PERRY ET AL: "Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 203, no. 2, 27 January 2007 (2007-01-27), pages 293-301, XP005737573, ISSN: 0014-4886, DOI: 10.1016/J.EXPNEUROL.2006.09.028 (B1)

US-A1- 2005 209 142 (B1)

US-B2- 7 576 050 (B1)

WO-A2-2007/120899 (B1)

MARTIN BRONWEN ET AL: "Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.", DIABETES FEB 2009 LNKD- PUBMED:18984744, vol. 58, no. 2, February 2009 (2009-02), pages 318-328, XP002684936, ISSN: 1939-327X (B1)